

Prescription & Enrollment Form
Oncology (oral) (T-Z)



677 Ala Moana Blvd., Suite 404,
 Honolulu, HI 96813-5412

Four simple steps to submit your referral.

1 PATIENT INFORMATION

New patient Current

Patient's first name _____
 Last name _____ Middle initial _____
 Date of birth _____ Male Female Last 4 digits of SSN _____
 Street address _____ Apt # _____
 City _____ State _____ Zip _____
 Parent/guardian (if applicable) _____
 Home phone _____ Work phone _____ Cell phone _____
 Evening phone _____ E-mail address _____
 Patient's primary language: English Other If other, please specify _____

Please attach copies of front and back of patient's insurance cards or complete information below.

Insurance company _____ Phone _____
 Insured's name _____
 Insured's employer _____ Relationship to patient _____
 Identification # _____ Policy/group # _____
 Prescription card: Yes No If yes, carrier _____
 Policy # _____ Group # _____ Is patient eligible for Medicare? Yes No
 Does patient have a secondary insurance? Yes No

2 PRESCRIBER INFORMATION

All fields must be completed to expedite prescription fulfillment.

Date _____ Time _____ Date medication needed _____
 Prescriber's first name _____ Last name _____
 Prescriber's title _____
 If NP or PA, under direction of Dr. _____
 Office contact and title _____
 Office contact e-mail _____
 Office/clinic/institution name _____
 Clinic/hospital affiliation _____
 Street address _____ Suite # _____
 City _____ State _____ Zip _____
 Phone _____ Fax _____
 NPI # _____ License # _____

3 CLINICAL INFORMATION

Primary ICD-10 code: _____
 Current weight _____ kg/lbs Height _____ inches/cm
 BSA _____ m² Date obtained _____
 NKDA Known drug allergies _____
 Concurrent meds _____

4 PRESCRIBING INFORMATION

Medication	Strength/Formulation	Directions	Quantity/Refills
<input type="checkbox"/> Talzenna® (talazoparib)	<input type="checkbox"/> 0.25mg capsule <input type="checkbox"/> 1mg capsule	<input type="checkbox"/> Take _____ mg by mouth daily <input type="checkbox"/> Other _____ A dose titration/reduction can be prescribed in order to manage tolerability.	Quantity _____ Days supply _____ Refills _____
<input type="checkbox"/> Taspigna® (nilotinib)	<input type="checkbox"/> 150mg capsule (28 capsules per pack) <input type="checkbox"/> 200mg capsule (28 capsules per pack)	<input type="checkbox"/> Take _____ capsule(s) twice daily <input type="checkbox"/> Other _____	Qty of packs _____ Days supply _____ Refills _____
<input type="checkbox"/> Temodar® (temozolomide)	<input type="checkbox"/> 5mg capsule _____ qty <input type="checkbox"/> 20mg capsule _____ qty <input type="checkbox"/> 100mg capsule _____ qty <input type="checkbox"/> 140mg capsule _____ qty <input type="checkbox"/> 180mg capsule _____ qty <input type="checkbox"/> 250mg capsule _____ qty	<input type="checkbox"/> Take _____ mg once daily for _____ days on and _____ days off <input type="checkbox"/> Other _____ Please see "Other" below to prescribe antiemetic agent if necessary.	Days supply _____ Refills _____
<input type="checkbox"/> Tykerb® (lapatinib)	<input type="checkbox"/> 250mg tablet	<input type="checkbox"/> Take 5 tablets once daily <input type="checkbox"/> Other _____	Quantity _____ Days supply _____ Refills _____
<input type="checkbox"/> Vizimpro® (dacomitinib)	<input type="checkbox"/> 15mg tablet <input type="checkbox"/> 30mg tablet <input type="checkbox"/> 45mg tablet	<input type="checkbox"/> Take _____ mg once daily <input type="checkbox"/> Other _____	Quantity _____ Days supply _____ Refills _____
<input type="checkbox"/> Votrient® (pazopanib)	<input type="checkbox"/> 200mg tablet	<input type="checkbox"/> Take 4 tablets once daily <input type="checkbox"/> Other _____	Quantity _____ Days supply _____ Refills _____
<input type="checkbox"/> Xalkori® (crizotinib)	<input type="checkbox"/> 200mg tablet <input type="checkbox"/> 250mg tablet	<input type="checkbox"/> Take one tablet twice daily <input type="checkbox"/> Other _____	Quantity _____ Days supply _____ Refills _____
<input type="checkbox"/> Xeloda® (capecitabine)	<input type="checkbox"/> 150mg tablet _____ qty <input type="checkbox"/> 500mg tablet _____ qty	<input type="checkbox"/> Take _____ mg twice daily for _____ days with _____ days off <input type="checkbox"/> Other _____	Days supply _____ Refills _____
<input type="checkbox"/> Xtandi® (enzalutamide)	<input type="checkbox"/> 40mg capsule	<input type="checkbox"/> Take 4 capsules once daily <input type="checkbox"/> Other _____	Quantity _____ Days supply _____ Refills _____
<input type="checkbox"/> Other _____			Quantity _____ Days supply _____ Refills _____

By signing below, I certify that the above therapy is medically necessary. I also authorize Accredo to initiate any de minimus authorization processes from applicable health plans, if needed, including the submission of any necessary forms to such health plans, to the extent not prohibited.

Prescriber's signature (sign below) (Physician attests this is his/her legal signature. **NO STAMPS**)

PHYSICIAN SIGNATURE REQUIRED

Date _____ Dispense as written _____ Date _____ Substitution allowed _____

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Please fax completed form to the Oncology team at 808.650.6487. To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names, or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners.